Logo

Genesis Genomics Pockets $306K to Develop Cancer Dx

Dec 14, 2007
NEW YORK (GenomeWeb News) - Genesis Genomics has received a CAN$311,735 (US$ 305,540) investment from the Ontario provincial government to fund its mitochondrial DNA-based diagnostic tests for cancer, the firm’s controller, Carole McCollum, told GenomeWeb News today.
 
The Thunder Bay, Ontario-based company will use the funds from the Northern Ontario Heritage Fund to continue to develop and commercialize a diagnostic test for prostate cancer and to develop an early-stage breast cancer test, McCollum said.
 
Last month, Genesis Genomics was awarded part of a CA$465,000 Natural Science and Engineering grant to work with Genoma and two Canadian universities to develop and sell a handheld device that would rapidly identify a species based on its DNA sequences.

Breaking News
The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.